Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Kassambara, Alboukadel ^a   Schoenhals, Matthieu ^a   Moreaux, Jérôme ^b   Veyrune, Jean Luc ^b   Rème, Thierry ^a   Goldschmidt, Hartmut ^c   Hose, Dirk ^c   Klein, Bernard ^a,b,d  

^a INSERM   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; DEP DOMAIN CONTAINED PROTEIN 1A; INTERLEUKIN 6 RECEPTOR; PROTEIN P21; PROTEIN P53; TUMOR PROTEIN; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DEPDC1 PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN;

ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DEP DOMAIN CONTAINED PROTEIN 1A GENE; DISEASE MARKER; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; ONCOGENE; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; SURVIVAL RATE; APOPTOSIS; BONE MARROW CELL; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; MORTALITY; MUTATION; PATHOLOGY; PHOSPHORYLATION; PLASMA CELL; PROGNOSIS; RNA INTERFERENCE; TUMOR CELL LINE;

APOPTOSIS; BONE MARROW CELLS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GTPASE-ACTIVATING PROTEINS; HUMANS; MULTIPLE MYELOMA; MUTATION; NEOPLASM PROTEINS; PHOSPHORYLATION; PLASMA CELLS; PROGNOSIS; PROTEIN STABILITY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84876959579     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062752     Document Type: Article

References (45)

1. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, et al. (2009) International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23: 2210-2221.
2. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, et al. (2006) The molecular classification of multiple myeloma. Blood 108: 2020-2028.
3. Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, et al. (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109: 2276-2284.
4. Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, et al. (2008) Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol 26: 4798-4805.
5. Hose D, Reme T, Hielscher T, Moreaux J, Meissner T, et al. (2011) Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma. Haematologica 96: 87-95.
6. Hose D, Reme T, Meissner T, Moreaux J, Seckinger A, et al. (2009) Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 113: 4331-4340.
7. Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, et al. (2009) Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene 28: 3866-3879.
8. Kassambara A, Hose D, Moreaux J, Walker BA, Protopopov A, et al. (2012) Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica 97: 622-630.
9. Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, et al. (2011) A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 96: 574-582.
10. Chibon F, Lagarde P, Salas S, Perot G, Brouste V, et al. (2010) Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 16: 781-787.
11. Lemee F, Bergoglio V, Fernandez-Vidal A, Machado-Silva A, Pillaire MJ, et al. (2010) DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. Proc Natl Acad Sci U S A 107: 13390-13395.
12. Pillaire MJ, Selves J, Gordien K, Gourraud PA, Gentil C, et al. (2010) A 'DNA replication' signature of progression and negative outcome in colorectal cancer. Oncogene 29: 876-887.
13. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z, (2006) A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38: 1043-1048.
14. Christensen JH, Jensen PV, Kristensen IB, Abildgaard N, Lodahl M, et al. (2012) Characterization of potential CD138 negative myeloma "stem cells". Haematologica 97: e18-20.
15. Chiron D, Surget S, Maiga S, Bataille R, Moreau P, et al. (2012) The peripheral CD138+ population but not the CD138- population contains myeloma clonogenic cells in plasma cell leukaemia patients. Br J Haematol 156: 679-683.
16. Kim D, Park CY, Medeiros BC, Weissman IL (2012) CD19(-)CD45(low/-)CD38(high)/CD138(+) plasma cells enrich for human tumorigenic myeloma cells. Leukemia.
17. Greipp PR, Raymond NM, Kyle RA, O'Fallon WM, (1985) Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 65: 305-310.
18. Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, et al. (2011) Identification of early molecular markers for breast cancer. Mol Cancer 10: 15.
19. Harada Y, Kanehira M, Fujisawa Y, Takata R, Shuin T, et al. (2010) Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. Cancer Res 70: 5829-5839.
20. Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, et al. (2011) Identification of Genes Up-regulated in ALK-positive and EGFR/KRAS/ALK-negative Lung Adenocarcinomas. Cancer Res.
21. M Kanehira YH, R Takata, T Shuin, T Miki, T Fujioka,et al. (2007) Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene 26: 6448-6455.
22. Jego G, Robillard N, Puthier D, Amiot M, Accard F, et al. (1999) Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 94: 701-712.
23. Jourdan M, Caraux A, De Vos J, Fiol G, Larroque M, et al. (2009) An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood 114: 5173-5181.
24. Cazzalini O, Scovassi AI, Savio M, Stivala LA, Prosperi E, (2010) Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. Mutat Res 704: 12-20.
25. Smith J, Tho LM, Xu N, Gillespie DA, (2010) The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 108: 73-112.
26. Hill R, Lee PW, (2010) The DNA-dependent protein kinase (DNA-PK): More than just a case of making ends meet? Cell Cycle 9: 3460-3469.
27. Medugno L, Florio F, De Cegli R, Grosso M, Lupo A, et al. (2005) The Kruppel-like zinc-finger protein ZNF224 represses aldolase A gene transcription by interacting with the KAP-1 co-repressor protein. Gene 359: 35-43.
28. Friedman JR, Fredericks WJ, Jensen DE, Speicher DW, Huang XP, et al. (1996) KAP-1, a novel corepressor for the highly conserved KRAB repression domain. Genes Dev 10: 2067-2078.
29. Vitale I, Galluzzi L, Castedo M, Kroemer G, (2011) Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 12: 385-392.
30. Kallies A, Hasbold J, Fairfax K, Pridans C, Emslie D, et al. (2007) Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1. Immunity 26: 555-566.
31. Ancelin K, Lange UC, Hajkova P, Schneider R, Bannister AJ, et al. (2006) Blimp1 associates with Prmt5 and directs histone arginine methylation in mouse germ cells. Nat Cell Biol 8: 623-630.
32. Lupo A, Cesaro E, Montano G, Izzo P, Costanzo P, (2011) ZNF224: Structure and role of a multifunctional KRAB-ZFP protein. Int J Biochem Cell Biol 43: 470-473.
33. Jourdan M, Caraux A, Caron G, Robert N, Fiol G, et al. (2011) Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J Immunol 187: 3931-3941.
34. Hose D, Reme T, Hielscher T, Moreaux J, Messner T, et al. (2011) Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 96: 87-95.
35. Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, et al. (1998) Plasmablastic morphology-An independent prognostic factor with clinical and laboratory correlates: eastern cooperative oncology group (ECOG) myeloma trial E9486 report by the ECOG myeloma laboratory group [In Process Citation]. Blood 91: 2501-2507.
36. Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, et al. (1994) Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83: 3654-3663.
37. Gu ZJ, Vos JD, Rebouissou C, Jourdan M, Zhang XG, et al. (2000) Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia 14: 188-197.
38. Rebouissou C, Wijdenes J, Autissier P, Tarte K, Costes V, et al. (1998) A gp130 Interleukin-6 Transducer-Dependent SCID Model of Human Multiple Myeloma. Blood 91: 4727-4737.
39. De Vos J, Thykjaer T, Tarte K, Ensslen M, Raynaud P, et al. (2002) Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene 21: 6848-6857.
40. Cremer FW, Bila J, Buck I, Kartal M, Hose D, et al. (2005) Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 44: 194-203.
41. Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, et al. (2006) Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 107: 2633-2638.
42. Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, et al. (2005) The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106: 1021-1030.
43. Jourdan M, Mahtouk K, Veyrune JL, Couderc G, Fiol G, et al. (2005) Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors. Eur Cytokine Netw 16: 57-64.
44. Reme T, Hose D, De Vos J, Vassal A, Poulain PO, et al. (2008) A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments. BMC Bioinformatics 9: 16.
45. Tanguy Le Carrour SA, Sylvie Tondeur, Ludovic Lhermitte, Ned Lamb, Thierry Reme, et al. (2010) Amazonia!: An Online Resource to Google and Visualize Public Human whole Genome Expression Data. The Open Bioinformatics Journal 4 5-10.